{
    "clinical_study": {
        "@rank": "136206", 
        "acronym": "CITADEL", 
        "arm_group": {
            "arm_group_label": "CMD-003", 
            "arm_group_type": "Experimental", 
            "description": "Treatment consists of two injections of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.\nSubjects without clinical signs of disease progression at the week 8 assessment will be eligible for up to 3 additional injections of 2x10E7 cells/m2 administered at week 8, month 3 and month 6."
        }, 
        "brief_summary": {
            "textblock": "To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients\n      with aggressive EBV positive extranodal NK/T-cell lymphoma"
        }, 
        "brief_title": "Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma", 
        "condition": [
            "Lymphoma, Extranodal NK-T-Cell", 
            "EBV"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Extranodal NK-T-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "FOR SCREENING PHASE:\n\n        Inclusion Criteria:\n\n          1. Diagnosis of extranodal NK/T lymphoma, perWHO classification, 4th ed., which must\n             include EBV tumor positivity, measured either by EBV encoded RNA (EBER) or LMP1\n             immunostaining.\n\n          2. a) Clinically suspected or documented relapse/progression, at any time following at\n             least one cycle of an asparaginase-based chemotherapy OR b) High-risk disease (stage\n             III/IV, KPI groups 3-4 or IPI intermediate-high) at any time (regardless of\n             chemotherapy status and disease relapse/ progression)\n\n          3. Male or female \u2265 18 years of age.\n\n          4. Weigh \u2265 35 kg.\n\n          5. ECOG performance score 0-2, inclusively.\n\n          6. Negative \u03b2-hCG test in women of childbearing potential.\n\n          7. Able to understand and comply with the requirements of the study and to provide\n             written informed consent.\n\n        Exclusion Criteria:\n\n          1. CNS lymphoma.\n\n          2. NK cell leukemia.\n\n          3. Hemophagocytic lymphohistiocytosis.\n\n          4. Positive laboratory test for anti-HIV 1,2; HBsAg, anti-HTLV-I; anti-HCV, or syphilis\n             (Patients with anti-hepatitis B core antibody are eligible if negative for HBsAg).\n\n          5. Use of systemic corticosteroids >0.5 mg/kg/day within 10 days prior to obtaining 100\n             mL whole blood starting material.\n\n          6. Patient is pregnant or lactating.\n\n          7. Female patient of childbearing potential unwilling to use effective birth control\n             (barrier methods, oral contraceptives and/or intrauterine devices) during the entire\n             duration of the study (or the patient must be surgically sterile with documentation\n             in the patient's medical records).\n\n          8. Sexually active patients unwilling to utilize one of the more effective birth control\n             methods during the study and for 6 months after the study treatment is concluded. The\n             male partner should use a condom.\n\n          9. Clinically significant medical condition e.g. pulmonary, neurological,\n             cardiovascular, metabolic, that could jeopardize patient safety, interfere with the\n             objectives of the protocol, or limit patient compliance with study requirements, as\n             determined by the Investigator.\n\n         10. Active second malignancy.\n\n         11. Previous non-hematological malignancy, except for adequately treated basal-cell\n             carcinoma of skin or cervical carcinoma in-situ without current evidence of disease,\n             unless the tumor was treated with curative intent more than 5 years prior to study\n             entry.\n\n         12. Any prior allogeneic hematopoietic stem cell transplant.\n\n        FOR TREATMENT PHASE:\n\n        Inclusion Criteria:\n\n          1. All Screening Phase inclusion criteria.\n\n          2. Documented relapse or progression following at least one prior cycle of an\n             asparaginase-containing chemotherapy regimen.\n\n          3. At least one prior cycle of gemcitabine-based salvage chemotherapy.\n\n          4. a) Presence of measurable disease as defined by the modified Response Evaluation\n             Criteria in Solid. Tumors (RECIST v1.1) as described in the protocol (assigned to Arm\n             A). OR b) No measurable disease with complete or partial response following at least\n             one cycle of gemcitabine-based salvage chemotherapy (assigned to Arm B)\n\n          5. Completed most recent course of chemotherapy at least 2 weeks prior to first study\n             drug dose.\n\n          6. Recovery from acute hematological, hepatic and renal chemotherapy-related toxicities\n             as defined by\n\n             \u2264 Grade 1 according to NCI CTCAE v4.0.\n\n          7. Life expectancy \u2265 8 weeks.\n\n          8. Pulse oximetry of \u2265 90% on room air.\n\n        Exclusion Criteria:\n\n          1. All Screening Phase exclusion criteria.\n\n          2. Use of any investigational agents within prior 4 weeks.\n\n          3. Radiotherapy within prior 3 weeks.\n\n          4. Major surgery within prior 2 weeks.\n\n          5. Systemic corticosteroids within 24 hours prior to study drug administration.\n\n          6. Symptoms of cardiac failure with New York Heart Association classification of III or\n             IV.\n\n          7. Clinically significant medical condition e.g. infection, pulmonary, neurological,\n             cardiovascular, metabolic, that could jeopardize patient safety, interfere with the\n             objectives of the protocol, or limit patient compliance with study requirements, as\n             determined by the Investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948180", 
            "org_study_id": "CM-2013-01"
        }, 
        "intervention": {
            "arm_group_label": "CMD-003", 
            "intervention_name": "CMD-003", 
            "intervention_type": "Biological", 
            "other_name": "Autologous EBV-specific T-cells"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20010"
                    }, 
                    "name": "Children's National Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "John Theurer Cancer Center at Hackensack UMC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "New York-Presbyterian/Weill Cornell"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "The Ohio State University Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Baylor College of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20099"
                    }, 
                    "name": "Askelpios Klinik St Georg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "Samsung Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120-752"
                    }, 
                    "name": "Yonsei University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }, 
                    "name": "Asan Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M20 4BX"
                    }, 
                    "name": "The Christie Clinic"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Korea, Republic of", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)", 
        "other_outcome": [
            {
                "measure": "Immunological assessment of EBV-specific T-cell activity and phenotyping", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Monitor levels of plasma and whole blood EBV DNA (viral load)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "overall_official": [
            {
                "affiliation": "Baylor College of Medicine", 
                "last_name": "Helen Heslop, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cell Medica", 
                "last_name": "Kurt Gunter, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Germany: Ministry of Health", 
                "France: Ministry of Health", 
                "South Korea: Korea Food and Drug Administration (KFDA)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Disease response will be evaluated per Cheson 2007 at baseline, Week 8 and then every 3-4 months thereafter for one year.  Patient response to treatment will be determined by an independent radiological endpoint adjudication and assessment committee (EAAC).", 
            "measure": "Assess overall response rate (ORR = CR + PR)", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948180"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response duration", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Cell Medica Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cell Medica Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}